{Reference Type}: Journal Article
{Title}: Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy.
{Author}: Vodárek P;Écsiová D;Řezáčová V;Souček O;Šimkovič M;Vokurková D;Belada D;Žák P;Smolej L;
{Journal}: Cancer Med
{Volume}: 13
{Issue}: 15
{Year}: 2024 Aug
{Factor}: 4.711
{DOI}: 10.1002/cam4.7399
{Abstract}: <B>BACKGROUND: </B>The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied.<BR><B>METHODS: </B>We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first-line treatment. Fifty-five patients were evaluated again after the treatment with CIT.<BR><B>RESULTS: </B>We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1.<BR><B>CONCLUSIONS: </B>CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.